UNSPSC 51342805: Delavirdine mesilate or mesylate

This classification denotes a reverse transcriptase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 421105KRQE. European Medicines Agency schedules Delavirdine mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01575MIG. Delavirdine mesylate generally arises in the molecular formula C22H28N6O3S.CH4O3S. The term 'delavirdine mesylate' is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule delavirdine mesylate under HS 29350090 and SITC 51580.

As of Q4 2014, DELAVIRDINE MESYLATE remains US FDA's Preferred Term for this commodity. Delavirdine mesylate bears US NLM identifiers UMLS ID C0543492 and NCI Concept Code C28974. SMILES: CC(C)NC1CCCNC1N2CCN(CC2)C(=O)C3CC4CC(CCC4[NH]3)NS(=O)(=O)C.CS(=O)(=O)O.

UNSPSC 51342805 Delavirdine mesilate or mesylate is a Commodity code that nominally addresses a specific antiretroviral pharmaceutical product, but recent state and local procurement activity under this code does not involve delavirdine. Instead, issuing bodies are using the code to tag purchases of other pharmaceutical products and medical supplies — including antibiotics, opioid antagonists, and drug deactivation systems — suggesting either misclassification in vendor systems or repurposing of the code across broader pharmaceutical categories. The work being solicited involves sourcing pharmaceutical inventory for public health agencies and county health departments, typically through cooperative purchasing vehicles or competitive sealed bidding, with delivery to specified public facilities and compliance requirements around drug-free workplace certification and federal environmental regulations where FEMA funding is involved.

Recent activity appears concentrated in Florida and Illinois. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, for supply of Doxycycline Hyclate and Ciprofloxacin Hydrochloride under an IFB (Bid Number 26-482DPH-PREPD-B-53392), with a total award of $2,999,999.11 over the three-year contract term including renewals. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023 (note: date appears inconsistent with posting date). Neither opportunity names the code explicitly in the source material; bidders should verify code applicability before pursuing opportunities tagged under this number.